Here we go again...
There is nothing but one fiasco after another @ AP.
Whatever individual "fiasco" you're referring to upfront is not in a bubble.
Just add it to the entire mix of bullsh!t.
Also, there were ZERO statistically significant endpoints in the COVID-19 study.
I don't care how many ways you try to spin it the facts are the facts.
Does AP have a legitimate reason to push for a Ph3 COVID-19 study?
Maybe, IF it doesn't require another blood sacrifice by common shareholders and making PP holders rich with dirt cheap shares and giveaway warrants.
The bottom line is AP is running out of time and room to continue spinning one excuse after another for not getting to data in a reasonable timeline.
THE CEO IS A LIAR.
The BS ABOUT A JAPANESE SUPPLIER/MANUFACTURER NOT WILLING TO SHIP IFENPRODIL ELSEWHERE TO RUN/RECRUIT THE IPF/CC IS SOME STRAIGHT UP BULLSH!T
The IPF/CC FIASCO should get any CEO FIRED for having pigeonholed it's #1 clinical trial out the gate by claiming to save 600k in tax rebates. THEN LIE ABOUT IT ON FACEBOOK LIVE!
It was a bonehead amateur move (Christopher Moreau is playing checkers not chess) when you add up the cost of raising money in the interim to keep sh!t afloat until such time data can be collected and reported.
The CEO knew going in that enrollment in AU/NZ would be a huge challenge. Yet he did it anyway and knew further dilution would follow it and more is likely on the way.
Christopher Moreau is not a smart cookie at this bio stuff. He's trying to learn on the fly. He's making colossal mistakes at our expense and he needs to be held accountable for it.
It'll continue to be one excuse after another for delays and simply not getting sh!t done on a reasonable timeline that everybody else in bio world around us is getting done.
Moreau needs to shut his trap about Bellus Health. AP can't hold a candle to Bellus Health and their depth of knowledge with their entire team.
That's another one of his made up go to stories he like to peddle to shareholders as if AP would get to a $500M market cap anytime soon. Much less a $900M market cap at Bellus Healths 52 week hi.
As I've said here before, the EOP2 Meeting is AP's last shot this year at gaining any significant momentum for the stock.
If Moron Moreau comes away from the EOP@ meeting with a news release simply stating positive feedback from FDA without a mention of any outside entity helping with a Ph3 COVID trial AP is toast.
There's nothing going on but more BS stories about a Ph1 study for psycho drugs and a wait and wait and wait until next year for data from the IPF/CC study..
The CEO and Board of Directors are losers in pennyland. They enrich themselves. That's job #1.
Meanwhile, have @ it!
M$
News 
Market Data 
Discover 
